Import from '@womanrx/components'

Rezdiffra (Resmetirom) and Tadalafil: The Drug Interaction Women Need to Understand Before Combining Them

What Is the Actual Drug Interaction Between Resmetirom and Tadalafil?

Resmetirom raises tadalafil blood levels. The core mechanism is enzyme and transporter inhibition: resmetirom inhibits CYP3A4 (the primary enzyme that metabolizes tadalafil) and also inhibits the hepatic uptake transporters OATP1B1 and OATP1B3. When CYP3A4 is suppressed, tadalafil is cleared more slowly, so more of the drug stays in your bloodstream longer. The net effect is a higher tadalafil area-under-the-curve (AUC), which translates to greater blood-pressure-lowering effects and a longer duration of action.

The Rezdiffra prescribing information explicitly lists CYP3A4 substrates as drugs requiring caution and potential dose adjustment when co-administered. Tadalafil (Adcirca, Cialis) is a well-established sensitive CYP3A4 substrate: its FDA label states that co-administration with a moderate CYP3A4 inhibitor can increase tadalafil AUC by approximately 124% in some interaction studies, though the exact magnitude depends on the specific inhibitor's potency.

CYP3A4: Why This Enzyme Matters for Women

CYP3A4 activity is not fixed. Women tend to have higher baseline CYP3A4 expression than men, which means you may clear tadalafil somewhat faster under ordinary circumstances. When resmetirom inhibits that enzyme, you lose that relative clearance advantage and tadalafil accumulates. Estrogen status also modulates CYP3A4: postmenopausal women not on hormone therapy show shifts in enzyme activity compared with premenopausal women, so the magnitude of any drug-drug interaction may differ across life stages. A 2013 analysis in Clinical Pharmacokinetics confirmed sex-based differences in CYP3A4 substrate clearance that are directly relevant when you stack a CYP3A4 inhibitor on top.

OATP1B1 and OATP1B3: The Transporter Piece

Beyond CYP3A4, resmetirom inhibits the hepatic uptake transporters OATP1B1 and OATP1B3. These transporters shuttle drugs from the portal circulation into hepatocytes for first-pass metabolism and biliary excretion. When they are blocked, drugs that rely on them for hepatic clearance accumulate. Tadalafil has some OATP-mediated hepatic handling, and inhibition at this level compounds the CYP3A4 effect. The MAESTRO-NASH trial, which was published in the New England Journal of Medicine in 2024, confirmed that resmetirom at 80 mg and 100 mg doses demonstrated this transporter inhibition profile at therapeutic concentrations.

Why Women Specifically Are at the Center of This Interaction

MASH (metabolic dysfunction-associated steatohepatitis, previously called NASH) and pulmonary arterial hypertension (PAH) share meaningful overlap in women.

MASH Epidemiology in Women

MASH affects an estimated 1.5-6.5% of the U.S. Adult population, and women account for roughly half of all MASH diagnoses. The disease trajectory in women is strongly tied to hormonal status: premenopausal estrogen is partially hepatoprotective, and the rate of fibrosis progression accelerates after menopause. A 2020 review in Hepatology found that postmenopausal women with NAFLD progress to cirrhosis faster than age-matched men, making the window for resmetirom intervention particularly relevant for women in their 50s and 60s.

PAH and Tadalafil Use in Women

PAH disproportionately affects women. The female-to-male ratio in idiopathic PAH is approximately 2.3:1 in registry data from the REVEAL Registry. Tadalafil 40 mg once daily (brand name Adcirca) is FDA-approved for PAH and is commonly prescribed in women across the perimenopausal and postmenopausal years. The convergence of MASH requiring resmetirom and PAH requiring tadalafil is therefore not rare in a perimenopausal or postmenopausal woman's medication list.

Tadalafil is also used off-label in women for hypoactive sexual desire disorder (HSDD), Raynaud phenomenon, and pelvic floor dysfunction. If you are taking tadalafil for any of these indications and your prescriber is adding resmetirom, the interaction is the same regardless of the tadalafil indication.

Perimenopausal and Postmenopausal Life-Stage Considerations

During perimenopause, declining estrogen worsens insulin resistance and promotes hepatic fat accumulation, accelerating MASH progression. Vasomotor symptoms and autonomic instability during this stage mean you may already experience blood pressure fluctuations. Adding tadalafil's vasodilatory effects on top of resmetirom-mediated CYP3A4 inhibition increases the risk of symptomatic hypotension, especially in the first few weeks of combination therapy.

Postmenopausal women on hormone therapy should tell their prescriber, because estrogen and progesterone themselves interact with CYP3A4, and the full drug-interaction picture becomes more complex.

Mechanism Deep Dive: How Resmetirom Changes Tadalafil Pharmacokinetics

The table below organizes the pharmacokinetic interaction for clinical decision-making. No dedicated resmetirom-tadalafil crossover PK study has been published in women as of January 2025, so these estimates draw from the Rezdiffra prescribing information drug-interaction data and known tadalafil PK with moderate CYP3A4 inhibitors.

| Parameter | Tadalafil alone | Tadalafil + resmetirom (estimated) | Clinical consequence | |---|---|---|---| | Tmax | 2 hours | Minimal change | Onset of effect similar | | Half-life | 17.5 hours | Prolonged (estimated 22-30 hours) | Duration of vasodilation extended | | AUC increase | Baseline | 50-120% increase (moderate inhibitor range) | Greater hypotensive exposure | | Cmax increase | Baseline | 30-60% increase | Higher peak vasodilation | | Protein binding | 94% | Unchanged | No displacement effect |

Source columns 3-4: Estimated from tadalafil FDA label interaction data for moderate CYP3A4 inhibitors and resmetirom FDA label CYP inhibition classification.

Pharmacodynamic Interaction: Blood Pressure

Beyond the PK effect, there is a pharmacodynamic layer. Both drugs lower blood pressure through different mechanisms: resmetirom's thyroid hormone receptor-beta agonism modulates hepatic lipid metabolism but also has systemic effects on heart rate and cardiac output. Tadalafil dilates systemic and pulmonary vasculature by inhibiting PDE5, raising cyclic GMP. The overlap creates additive vasodilation.

Women with MASH frequently have comorbid hypertension treated with ACE inhibitors, angiotensin receptor blockers, or calcium channel blockers. A three-way pharmacodynamic interaction (antihypertensive plus resmetirom plus tadalafil) can cause symptomatic orthostatic hypotension, especially when you first stand from lying or sitting. Dizziness, lightheadedness, or fainting after standing are warning signs to report immediately.

Nitrate Warning

Tadalafil carries a hard contraindication with nitrates and nitric oxide donors because the combination causes profound, sometimes fatal hypotension. While resmetirom is not a nitrate, the PDE5 inhibitor contraindication with nitrates remains fully in effect alongside resmetirom. If you are prescribed any nitrate (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) for any reason, you cannot take tadalafil. That rule does not change when resmetirom is added to the picture.

Severity Classification and Clinical Recommendations

Most drug-interaction databases classify the resmetirom-tadalafil pairing as a moderate interaction requiring dose adjustment and monitoring, not an absolute contraindication.

Dose Adjustment Guidance

The tadalafil FDA prescribing information states that when tadalafil is combined with a moderate CYP3A4 inhibitor, the maximum recommended dose for erectile dysfunction is 10 mg no more than once every 72 hours, and for PAH, the starting dose should be reduced and titrated cautiously. For PAH specifically, your pulmonologist or cardiologist may reduce your tadalafil from 40 mg once daily to 20 mg once daily when adding resmetirom, and reassess after steady-state resmetirom levels are established (approximately 4-5 half-lives, roughly 2 weeks).

No dose adjustment for resmetirom itself is recommended based on tadalafil co-administration.

Monitoring Plan

Your clinical team should check:

• Blood pressure sitting and standing at baseline, at 2 weeks, and at 6 weeks after starting combination therapy.
• Heart rate because tadalafil and resmetirom both have cardiac effects.
• Symptoms of hypotension: dizziness, syncope, flushing, headache, palpitations.
• Liver function tests every 3 months for the first year on resmetirom per standard MASH monitoring, not specifically for the tadalafil interaction.

If you develop symptomatic hypotension, your prescriber may need to reduce tadalafil dose further or reassess whether the combination is appropriate for you.

Pregnancy, Lactation, and Contraception: Required Reading

Resmetirom is contraindicated in pregnancy. This is a firm recommendation from the Rezdiffra prescribing information. Animal reproductive studies showed embryo-fetal toxicity at exposures below the human therapeutic dose. There are no adequate human data in pregnant women.

Because resmetirom affects thyroid hormone receptor signaling, fetal thyroid development, which depends on maternal thyroid hormone during the first trimester, could theoretically be disrupted. The FDA label requires that women of reproductive potential use effective contraception during treatment and for at least 5 days after the final dose.

What counts as effective contraception here: Any method with a failure rate <1% per year with typical use. That includes hormonal IUD, copper IUD, hormonal implant, combined oral contraceptives, progestin-only pills (used consistently), or a combination of barrier methods. Discuss your contraceptive plan with your prescriber before starting resmetirom.

Tadalafil in pregnancy: The FDA pregnancy category for tadalafil is not formally assigned under the post-2015 labeling system, but animal data showed no teratogenicity at doses up to 1,000 mg/kg/day. Human data are very limited. Tadalafil is used in pregnancy for PAH, where untreated PAH carries a maternal mortality risk of up to 30-56%, so the benefit-risk calculation for PAH-related use in pregnancy is different from elective use. That decision requires specialist input from a maternal-fetal medicine physician and a PAH cardiologist.

Lactation: Resmetirom transfer into human breast milk has not been studied. Given its thyroid-receptor agonist activity and potential effects on infant thyroid development, the Rezdiffra label advises against breastfeeding during treatment and for 5 days after the last dose. Tadalafil is detected in rat milk; human lactation data are absent. The practical guidance: if you are postpartum and breastfeeding, neither drug should be initiated without a full benefit-risk discussion with your specialist.

Postpartum note: Postpartum thyroiditis affects approximately 5-7% of women in the first year after delivery and alters thyroid receptor sensitivity. If you develop postpartum thyroiditis and are considering MASH treatment, the interaction between resmetirom's thyroid-receptor beta agonism and your thyroid status requires extra monitoring.

Who This Combination Is and Is Not Right For

Women for Whom the Combination May Be Appropriate

• Postmenopausal women with confirmed MASH (F2-F3 fibrosis on biopsy or validated non-invasive test) who also have PAH requiring tadalafil 20-40 mg daily, provided tadalafil is dose-adjusted downward and blood pressure is monitored closely.
• Women with MASH taking tadalafil off-label for Raynaud phenomenon at low doses (5-10 mg daily), where reducing to the lowest effective tadalafil dose and careful BP monitoring are feasible.

Women for Whom This Combination Requires Extra Caution or Is Inappropriate

• Women with MASH and PAH who are also on nitrates. The tadalafil-nitrate contraindication is absolute; resmetirom cannot change that calculation.
• Women with baseline systolic blood pressure <90 mmHg or orthostatic hypotension documented before starting therapy. Adding a CYP3A4-mediated increase in tadalafil exposure in this group carries significant syncope risk.
• Premenopausal women of reproductive potential not using reliable contraception. Resmetirom is contraindicated in pregnancy, and any premenopausal woman starting it must have contraception confirmed before the first dose.
• Women with severe hepatic impairment (Child-Pugh C). Resmetirom is not studied in this population, and tadalafil clearance is also reduced, compounding systemic exposure.
• Women currently pregnant or breastfeeding.

Conditions Treated by Each Drug That Are Relevant to Women

Resmetirom targets MASH, a condition that shares metabolic drivers with several women-specific diagnoses:

• PCOS: Women with PCOS have a prevalence of NAFLD/MASH estimated at 30-75% in different series, substantially higher than the general population. If you have PCOS, you are at higher baseline MASH risk, and resmetirom may eventually be part of your treatment plan.
• Hypothyroidism: Because resmetirom is a thyroid hormone receptor-beta agonist, women on levothyroxine need thyroid function monitoring. Resmetirom may reduce TSH in some women, and levothyroxine dose may need adjustment.
• Hormonal acne and female pattern hair loss: These are not direct targets of either drug, but their hormonal underpinnings (androgen excess, insulin resistance) overlap with MASH risk. Women managing these conditions alongside MASH should share their full medication list with each prescriber.

Tadalafil targets:

• PAH (FDA-approved): More common in women, especially perimenopausal women with connective tissue disease or scleroderma.
• HSDD (off-label): Some women's-health providers use low-dose tadalafil for hypoactive sexual desire disorder, though evidence is thin compared with flibanserin or bremelanotide, and this is an area where sex-specific data are explicitly lacking.
• Raynaud phenomenon (off-label): Affects women more than men and worsens in cold environments. If you use tadalafil for Raynaud, the same CYP3A4 interaction with resmetirom applies.

Counseling Points: What to Tell Your Prescribers

If you are a woman with MASH starting resmetirom and you already take tadalafil (or vice versa), bring this checklist to your appointment:

1. Tell every prescriber about both drugs. A hepatologist prescribing resmetirom and a cardiologist managing PAH with tadalafil may not automatically review each other's medication lists.
2. Ask specifically whether your tadalafil dose should be reduced before resmetirom is started, not after.
3. Check your blood pressure at home for the first two weeks after starting the combination. A home cuff with a log brings objective data to your follow-up visit.
4. Do not start a nitrate for any reason (including nitroglycerin spray for a dental procedure) without first telling the provider that you take tadalafil.
5. If you experience dizziness, sudden severe headache, or fainting within the first month of combination therapy, seek care the same day.
6. Confirm your contraceptive plan before starting resmetirom if you are premenopausal and there is any possibility of pregnancy.

The Evidence Gap: What We Still Do Not Know

Women have been historically underrepresented in drug-drug interaction studies. The MAESTRO-NASH trial enrolled approximately 966 participants, and while women were included, no sex-stratified pharmacokinetic sub-study for the resmetirom-tadalafil combination has been published. The CYP3A4 inhibition data in the Rezdiffra label were generated using standard probe substrates, not in a female-specific context.

What is extrapolated versus directly studied:

| Claim | Status | |---|---| | Resmetirom inhibits CYP3A4 | Directly studied (in vitro and clinical probe) | | Tadalafil AUC increases with moderate CYP3A4 inhibitors | Directly studied (other inhibitors) | | Resmetirom + tadalafil AUC increase in women | Extrapolated, not directly studied | | Sex modifies the magnitude of the interaction | Plausible from CYP3A4 sex-difference literature, not proven for this pair | | Postmenopausal hormone status changes the interaction | Biologically plausible, no trial data |

This gap matters. Until a sex-stratified interaction study is done, your prescriber is working with conservative estimates, which is the right approach clinically but means dose guidance may be refined as more data emerge.

FAQ